Study finds little difference in anti-VEGF treatment response of patients with wet AMD grouped by genetic risk profile

TORONTO — Genetic risk profile had no apparent impact on functional and anatomic reaction to anti-VEGF treatment in patients with wet AMD classified into three risk groups, according to a study presented here.“The difference in ETDRS letter gain and macular fluid reduction was not statistically significant between the three risk groups or the individual haplotype groups,” Varun Chaudhary, MD, FRCSC, and colleagues said in a poster presentation at the American Society of Retina Specialists meeting.The multi-centered, prospective, cohort study included 50 eyes of 50 patients who underwent a cheek swab DNA (Read more...)

Full Story →